onestepahead asked for suggestions to help get over Covid

New Post Public Reply Private Reply Replies (0) Message Board
Enjay onestepahead #127809
860
onestepahead asked for suggestions to help get over Covid more quickly. HHIGambler suggested Tollovid (via suggestion from misiu) to strengthen the immune system. I have not had Covid and don't have any suggestions, however, I keep Tollovid on hand in case I get it.

I just finished reading an article that discussed three drugs which probably won't help. In case someone suggests that you take one of these, I'll post some excerpts and the link below in case you want to read the entire article. Note that the patients in this study were obese, so it may not necessarily apply to those who are not obese.

I hope we can get back on track with Covid trials - it appears that field is still wide open.



Early treatment with three repurposed drugs -- metformin, ivermectin, or fluvoxamine -- did not prevent severe outcomes from COVID-19 in high-risk patients, according to a phase III randomized trial.

Among over 1,300 patients with overweight or obesity, the adjusted odds ratio for a primary event, including hypoxemia, an emergency department (ED) visit, hospitalization, or death, was 0.84 (95% CI 0.66-1.09, P=0.19) with metformin, 1.05 (95% CI 0.76-1.45, P=0.78) with ivermectin, and 0.94 (95% CI 0.66-1.36, P=0.75) with fluvoxamine, compared with placebo, reported Carolyn T. Bramante, MD, MPH, of the University of Minnesota in Minneapolis, and colleagues in the New England Journal of Medicine.

In prespecified secondary analyses, the adjusted odds ratios for an ED visit/hospitalization/death and hospitalization/death with the three drugs were:

0.58 (95% CI 0.35-0.94) and 0.47 (95% CI 0.20-1.11) with metformin
1.39 (95% CI 0.72-2.69) and 0.73 (95% CI 0.19-2.77) with ivermectin
1.17 (95% CI 0.57-2.40) and 1.11 (95% CI 0.33-3.76) with fluvoxamine

While a "possible benefit for the prevention of the more severe components of the primary endpoint ... was shown for metformin ... this finding was a prespecified secondary endpoint and thus cannot be considered to be definitive pending the results of other trials," Bramante and team wrote.

In an accompanying editorial, Salim S. Abdool Karim, MB, ChB, PhD, and Nikita Devnarain, PhD, of the Mailman School of Public Health at Columbia University in New York City, noted that doctors are doing more harm than good by using drugs that don't work, asking, "How much evidence of nonefficacy is enough?"

"Prescribing nonefficacious treatments is not a neutral or harmless option," they wrote, pointing out that not only does this practice keep patients from getting the right treatment, it also can lead to potential side effects and drug shortages for patients who need the drugs for other illnesses.

"Hence, it is important to have reliable evidence of nonefficacy and to have journals publish such studies," they continued. "It is also important that multiple rigorous randomized, controlled trials be performed to provide unequivocal evidence on the efficacy of new treatments."

"In keeping with evidence-based medical practice, patients with COVID-19 must be treated with efficacious medications; they deserve nothing less," they concluded.

For this double-blind, placebo-controlled study, which was conducted from Dec. 30, 2020 to Jan. 28, 2022, Bramante and colleagues included 1,323 patients (median age 46, 56% women) from six institutions. Six percent of the women were pregnant, and 52.2% of the overall group were vaccinated.

The primary composite endpoint was hypoxemia (≤93% oxygen saturation on home oximetry), an ED visit, hospitalization, or death.

https://www.medpagetoday.com/infectiousdiseas...definition

1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 0

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 24

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

T. Rowe Price OHA Credit Fund Reports Strong Q2 Performance

Updated Category News Views 146

Financial Performance Overview T. Rowe Price OHA Select Private Credit Fund (NASDAQ: OCREDIT) recently reported its financial results for the quarter ended June 30, 2025. The fund declared total distributions amounting to $0.81 per share for this period. This reflects the growing significance of private credit as a financing solution in today's credit markets. Investment...

Continue Reading
Toll Brothers Unveils Luxurious Townhome Community in Armonk

Updated Category News Views 222

Discover the Enclave at Armonk Located in Armonk, the newly launched Enclave at Armonk invites homebuyers to experience luxury living blended with convenience. This new community by Toll Brothers represents a significant addition to the Westchester County real estate market, bringing elegant townhome designs that promise sophistication and comfort. A Closer Look at the...

Continue Reading
XAI Octagon Trust Expands Opportunities with New Preferred Shares

Updated Category News Views 108

XAI Octagon Trust Issues Convertible Preferred Shares XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT), a diversified closed-end management investment company, has made a significant move by announcing the issuance and sale of 400,000 shares of its 6.95% Series II 2029 Convertible Preferred Shares. This initiative enhances the Trust's capital resources and...

Continue Reading
Endeavour Mining's Recent Share Buyback Activity Overview

Updated Category News Views 208

Endeavour Mining Announces Recent Share Buyback In a significant move for shareholders, Endeavour Mining plc (LSE: EDV, TSX: EDV) has disclosed its recent buyback of ordinary shares. These transactions showcase the company's ongoing commitment to enhancing shareholder value and demonstrate a strategic approach to managing its equity. Details of the Share Buyback Endeavour...

Continue Reading
Sleep Awareness Week 2025: Importance of Quality Sleep

Updated Category News Views 459

National Sleep Foundation Announces 2025 Dates for Sleep Awareness Week Today, the National Sleep Foundation (NSF) has shared that Sleep Awareness Week in 2025 will be observed from March 9 to March 15. This annual campaign aims to highlight the critical role sleep plays in promoting health and overall well-being, encouraging the public to prioritize high-quality sleep....

Continue Reading